Elevated Plasma miR-29a Levels Are Associated with Increased Carotid Intima-Media Thickness in Atherosclerosis

Cui-Zhong Liu1, Qi Zhong, Yu-Qing Huang

  • 1General Practice Centre, Hunan Provincial People's Hospital and The First Affiliated Hospital of Hunan Normal University.

Insights

Elevated levels of microRNA-29a (miR-29a) and reduced levels of adiponectin (APN) are linked to atherosclerosis. These findings suggest miR-29a may increase atherosclerosis risk, while APN may offer protection.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Atherosclerosis is a global health concern.
  • MicroRNA-29a (miR-29a) influences extracellular matrix and inflammation.
  • Adiponectin (APN) possesses anti-inflammatory properties.

Purpose of the Study:

  • To investigate the association between plasma miR-29a and APN levels with carotid intima-media thickness (cIMT) in atherosclerosis patients.
  • To determine the diagnostic and prognostic value of miR-29a and APN in atherosclerosis.

Main Methods:

  • Plasma miR-29a and APN levels were measured in 85 atherosclerosis patients (cIMT ≥ 1.2 mm) and 85 controls (cIMT < 1.2 mm).
  • Correlation analysis and multiple logistic regression were used to assess relationships.

Main Results:

  • Atherosclerosis patients had significantly higher miR-29a levels and lower APN levels compared to controls.
  • Increased cIMT positively correlated with miR-29a and negatively with APN.
  • Higher miR-29a levels increased atherosclerosis risk (OR: 1.136), while higher APN levels were protective (OR: 0.122).

Conclusions:

  • Elevated plasma miR-29a and reduced plasma APN are significantly associated with atherosclerosis.
  • miR-29a and APN show potential as biomarkers for atherosclerosis risk assessment.

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.7K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
667
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
538
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
668